What does PHARMALUX do?

PHARMALUX is a pharmacy in Antwerpen. Private Limited, started on 26 November 1992, 1 establishment.

What is the address of PHARMALUX?

The registered office of PHARMALUX is located at Te Boelaarlei 30, 2140 Antwerpen.

Is PHARMALUX still active?

Yes. According to the CBE (31 October 2026) PHARMALUX is active, legal situation “Normale toestand”, started on 26 November 1992.

Is PHARMALUX registered on Peppol?

Yes, PHARMALUX is registered on the Peppol network with ID 0208:0448761095.

What is the enterprise number of PHARMALUX?

The enterprise number of PHARMALUX is BE0448761095.

When was PHARMALUX founded?

PHARMALUX was founded on 26 November 1992.

Who are the directors of PHARMALUX?

According to the 2025 annual accounts, the directors of PHARMALUX are: Hans Monstrey, Godelieve Willemse.

Is PHARMALUX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 November 1992; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMALUX make in 2025?

PHARMALUX recorded a loss after taxes of € 43,360 in financial year 2025.

What is the revenue of PHARMALUX?

As a small company, PHARMALUX is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 111,636.

How much does an employee at PHARMALUX earn?

The average wage cost per full-time employee at PHARMALUX was € 43,000 in 2025: staff costs of € 150,390 for 3.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMALUX have?

According to the 2025 annual accounts, PHARMALUX has 3.5 full-time equivalents (FTE).

PHARMALUX (Private Limited) - Antwerpen - BE0448761095

Dossier PHARMALUX, printed on 31 October 2026 from databakkes.be/en/0448761095/pharmalux. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

PHARMALUX from Antwerpen, company number BE0448761095, closed financial year 2025 with a result of € -43,360 after tax. For that financial year PHARMALUX recorded a gross margin of € 111,636 and equity of € 1.3 million. Compared with financial year 2024, the result moved from € -662 to € -43,360. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.

What it is worth Healthy

€ 1.3 million

▼ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -43,360

▼ 6454 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 211,684

▼ 25% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 980,604.

People and assets in 2025

Full-time equivalents

3.5

▲ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 150,390

▲ 21% vs 2024

€ 43,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 901

▲ 272% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 55,564

▼ 12% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 26,988

▲ 42% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 131,657 Gross margin 2022: € 131,657 First fiscal year in the series	€ 121,028 Gross margin 2023: € 121,028 ▼ 8% vs 2022 (€ 131,657) Unfavourable step	€ 125,885 Gross margin 2024: € 125,885 ▲ 4% vs 2023 (€ 121,028) Favourable step	€ 111,636 Gross margin 2025: € 111,636 ▼ 11% vs 2024 (€ 125,885) Unfavourable step	▼ 11%
Profit after taxes	€ 22,819 Profit after taxes 2022: € 22,819 First fiscal year in the series	€ 2,326 Profit after taxes 2023: € 2,326 ▼ 90% vs 2022 (€ 22,819) Unfavourable step	€ -662 Profit after taxes 2024: € -662 ▼ € 2,988 vs 2023 (€ 2,326) Unfavourable step	€ -43,360 Profit after taxes 2025: € -43,360 ▼ € 42,699 vs 2024 (€ -662) Unfavourable step	▼ € 42,699
Equity	€ 1,307,760 Equity 2022: € 1,307,760 First fiscal year in the series	€ 1,310,087 Equity 2023: € 1,310,087 Unchanged (€ 1,307,760) Favourable step	€ 1,309,425 Equity 2024: € 1,309,425 Unchanged (€ 1,310,087) Unfavourable step	€ 1,266,065 Equity 2025: € 1,266,065 ▼ 3% vs 2024 (€ 1,309,425) Unfavourable step	▼ 3%
Total debts	€ 364,795 Total debts 2022: € 364,795 First fiscal year in the series	€ 83,177 Total debts 2023: € 83,177 ▼ 77% vs 2022 (€ 364,795) Favourable step	€ 117,063 Total debts 2024: € 117,063 ▲ 41% vs 2023 (€ 83,177) Unfavourable step	€ 119,202 Total debts 2025: € 119,202 ▲ 2% vs 2024 (€ 117,063) Unfavourable step	▲ 2%
Cash	€ 575,014 Cash 2022: € 575,014 First fiscal year in the series	€ 287,184 Cash 2023: € 287,184 ▼ 50% vs 2022 (€ 575,014) Unfavourable step	€ 284,120 Cash 2024: € 284,120 ▼ 1% vs 2023 (€ 287,184) Unfavourable step	€ 211,684 Cash 2025: € 211,684 ▼ 25% vs 2024 (€ 284,120) Unfavourable step	▼ 25%
Retained profit	€ 1,022,300 Retained profit 2022: € 1,022,300 First fiscal year in the series	€ 1,024,626 Retained profit 2023: € 1,024,626 Unchanged (€ 1,022,300) Favourable step	€ 1,023,965 Retained profit 2024: € 1,023,965 Unchanged (€ 1,024,626) Unfavourable step	€ 980,604 Retained profit 2025: € 980,604 ▼ 4% vs 2024 (€ 1,023,965) Unfavourable step	▼ 4%
Balance sheet total	€ 1,672,555 Balance sheet total 2022: € 1,672,555 First fiscal year in the series	€ 1,393,264 Balance sheet total 2023: € 1,393,264 ▼ 17% vs 2022 (€ 1,672,555) Unchanged	€ 1,426,488 Balance sheet total 2024: € 1,426,488 ▲ 2% vs 2023 (€ 1,393,264) Unchanged	€ 1,385,266 Balance sheet total 2025: € 1,385,266 ▼ 3% vs 2024 (€ 1,426,488) Unchanged	▼ 3%
Employees (FTE)	1.7 Employees (FTE) 2022: 1.7 First fiscal year in the series	2.5 Employees (FTE) 2023: 2.5 ▲ 0.8 vs 2022 (1.7) Unchanged	2.9 Employees (FTE) 2024: 2.9 ▲ 0.4 vs 2023 (2.5) Unchanged	3.5 Employees (FTE) 2025: 3.5 ▲ 0.6 vs 2024 (2.9) Unchanged	▲ 0.6

Key figures of PHARMALUX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMALUX?

What happened at PHARMALUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 27, 2026 New annual accounts for financial year 2025: loss of € 43,360. Source: NBB ↗
2023 Hans Monstrey became a director. NBB
2023 Godelieve Willemse became a director. NBB
Dec 23, 1992 New establishment in Antwerpen. KBO
Nov 26, 1992 Start of the company according to the CBE. KBO

In short

From € 22,819 profit in 2022 to € 43,360 loss in 2025.

Paid € 19,822 in corporate taxes since 2022.

Best year ever: 2022, with € 22,819 profit.

On average € 31,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Hans Monstrey

Godelieve Willemse

PHARMALUX

Zwitserse apotheek 99.7%

Bio-Homeopharma 99.3%

Behind PHARMALUX are Hans Monstrey and Godelieve Willemse. It owns 99.7% of Zwitserse apotheek and 99.3% of Bio-Homeopharma itself.

Directors

According to the 2025 annual accounts

Hans Monstrey

Director

Also active at: APOTEEK PRAATS, HARVEST HOLDINGS, Bio-Homeopharma, NAVECO-CONSULTING

since 2023

Godelieve Willemse

Director

Also active at: HARVEST HOLDINGS, Bio-Homeopharma, NAVECO-CONSULTING

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Te Boelaarlei 30

2140 Antwerpen

2.059.995.631

Dageraadplaats 25

2018 Antwerpen

Active since 23 December 1992

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

HARVEST HOLDINGS same network

€ 370,003 gross margin · 2025

NAVECO-CONSULTING same network

€ 81,153 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0448.761.095

VAT number

BE 0448.761.095

Registered office

Te Boelaarlei 30, 2140 Antwerpen

Names & denominations

PHARMALUX

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

26 November 1992

Peppol

Active · Active since 27 Mar 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Overige ondersteunende activiteiten in verband met financiële diensten, neg, exclusief verzekeringen en pensioenfondsen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMALUX

Warning lights

Financials

What happened to PHARMALUX?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions